The aim of an argument or discussion should not be victory, but
progress. -- Joseph Joubert
Attachment 1008
One of the leading vaccine's in phase 3 trails (Oxford/AstraZeneca) was place on hold recently following an adverse reaction by one of the test subjects.
But for now, the trial has resumed.
Oxford and AstraZeneca resume coronavirus vaccine trial.
By PAN PYLAS
Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in a U.K. patient.
In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday.
“The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said.
The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of the strongest contenders among the dozens of coronavirus vaccines in various stages of testing around the world.
Story Continues.
The aim of an argument or discussion should not be victory, but
progress. -- Joseph Joubert
Attachment 1008
New brain cell-like nanodevices
An electron micrograph of the artificial neuron.
In the September issue of the journal Nature, scientists from Texas A&M University, Hewlett Packard Labs and Stanford University have described a new nanodevice that acts almost identically to a brain cell. Furthermore, they have shown that these synthetic brain cells can be joined together to form intricate networks that can then solve problems in a brain-like manner.
"This is the first study where we have been able to emulate a neuron with just a single nanoscale device, which would otherwise need hundreds of transistors," said Dr. R. Stanley Williams, senior author on the study and professor in the Department of Electrical and Computer Engineering. "We have also been able to successfully use networks of our artificial neurons to solve toy versions of a real-world problem that is computationally intense even for the most sophisticated digital technologies."
In particular, the researchers have demonstrated proof of concept that their brain-inspired system can identify possible mutations in a virus, which is highly relevant for ensuring the efficacy of vaccines and medications for strains exhibiting genetic diversity.
More:
https://phys.org/news/2020-09-brain-...s-viruses.html
It's rather grim that in America we now have over 200 thousand dead and 7 million infected.
My inner Mulder wants to believe, but my inner Scully remains skeptical.
Last edited by CasperParks; 09-27-2020 at 09:07 PM.
Here is a dashboard to check your infection rate, it is county by county.
Select your state (or any state) on panel of the left . . . then park your mouse pointer over the county you wish to see.
https://globalepidemics.org/key-metr...d-suppression/
This next one is a "data-pak of info . . . you'll need to pan down to see all of it.
https://informationisbeautiful.net/v...phic-datapack/
. . . I probably posted these in the past . . .
A CDC data dump (cumulative data as of September 2020) reveals very, very good news. The survival rate for Coronavirus Covid-19 (if you become infected) looks to be very good for most people.
The newly released CDC data is all statistical information to date. That means it’s from the beginning of Covid-19 till now. It is not a snap shot of “a good last 2 weeks” (for example). It is a calculation of the fatality rate over the entire pandemic with the latest data inputs.
https://www.cdc.gov/coronavirus/2019...scenarios.html
The aim of an argument or discussion should not be victory, but
progress. -- Joseph Joubert
Attachment 1008
Updated Sept. 10, 2020
Summary of Recent Changes
Updated September 10, 2020:
The Infection Fatality Ratio parameter has been updated to include age-specific estimates
The parameter for Number of Days from Symptom Onset to Seeking Outpatient Care—which was based on influenza care seeking data—has been replaced with the Median Number of Days from Symptom Onset to SARS-CoV-2 Test among SARS-CoV-2 Positive Patients
A new parameter for the likelihood of an infection being reported has been added: The Ratio of Estimated Infections to Reported Case Counts
(epo333) - Even if the report is a month old, the data is the result of studies go back to the beginning . . .
. . . It still seems a lot better news then what I've heard in the past.This document was first posted on May 20, 2020, with the understanding that the parameter values in each scenario would be updated and augmented over time, as we learn more about the epidemiology of COVID-19. The September 10 update is based on data received by CDC through August 8, 2020.
I suppose those statistics must be for a person of that age, initially in good health (prior to infection).
Yesterday afternoon, when President Trump arrived at Walter Reid Naval hospital aboard Marine1 with a COVID-19 infection, the talking heads began discussing the effects of pre-existing conditions in addition to age group.
They listed the President as being 72yo, but they also listed him as being obese.
A few examples of other conditions would be respiratory problems/asthma, bad heart, kidney failure, etc.
In those cases, the talking heads said the odds of fatality approached 15%.
Not quite the rosy 2% the CDC would have us believe from their recent "overall" report.
Sorry to rain on your parade. Maybe the spokesman from Walter-Reid didn't know the latest stats.
I have noticed fatalities decline over the past months. No doubt medical facilites are getting better at keeping patients alive with more PPE and better treatment options like Remdesivir and Dexamethasone (steroids).
Reduction of patient infection rate would be another positive factor, slowing the rate of hospital admissions would assure everyone who needed an ICU bed and/or respirator could get treatment in a timely fashion.
The aim of an argument or discussion should not be victory, but
progress. -- Joseph Joubert
Attachment 1008